-
公开(公告)号：US11040059B2
公开(公告)日：2021-06-22
申请号：US15522466
申请日：2015-10-27
IPC分类号： A61K31/721 , A61K47/10 , A61K9/00 , A61K31/295
摘要： The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less.
-
公开(公告)号：US10414831B2
公开(公告)日：2019-09-17
申请号：US16178943
申请日：2018-11-02
发明人： Hans Andreasen
IPC分类号： C08B37/02 , C07H3/06 , A61K31/721 , A61K47/26
摘要： The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
-
公开(公告)号：US11851504B2
公开(公告)日：2023-12-26
申请号：US17142442
申请日：2021-01-06
发明人： Hans Andreasen
IPC分类号： C08B37/02 , C07H3/06 , A61K31/721 , A61K47/26
CPC分类号： C08B37/0021 , A61K31/721 , A61K47/26 , C07H3/06
摘要： The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
-
公开(公告)号：US11633489B2
公开(公告)日：2023-04-25
申请号：US17178430
申请日：2021-02-18
摘要： Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.
-
公开(公告)号：US12030962B2
公开(公告)日：2024-07-09
申请号：US17083366
申请日：2020-10-29
发明人： Hans Andreasen
IPC分类号： C08B37/02 , A61K31/721 , A61K47/26 , C07H3/06
CPC分类号： C08B37/0021 , A61K31/721 , A61K47/26 , C07H3/06
摘要： The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosacharride in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
-
公开(公告)号：US11471483B2
公开(公告)日：2022-10-18
申请号：US17182366
申请日：2021-02-23
摘要： The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, or pallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.
-
公开(公告)号：US11040064B2
公开(公告)日：2021-06-22
申请号：US15554762
申请日：2016-03-17
摘要： The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, orpallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.
-
公开(公告)号：US10960081B2
公开(公告)日：2021-03-30
申请号：US15572382
申请日：2016-06-22
IPC分类号： A61K31/706 , A61K31/7068 , A61K31/7072 , A61K31/708 , A61K47/61 , A61K33/26 , A61P3/02
摘要： Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.
-
公开(公告)号：US09439969B2
公开(公告)日：2016-09-13
申请号：US14307957
申请日：2014-06-18
发明人： Hans Andreasen
CPC分类号： C08B37/0021 , A61K47/26 , C07H3/06
摘要： The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
摘要翻译： 本发明涉及具有稳定性提高的铁寡糖化合物，其包含与羟基氧化氢稳定相关的氢化寡糖，所述氢化寡糖中二聚糖的含量为氢化寡糖的总重量的2.9重量％以下。 提供了另外的方面，制备所述化合物的方法以及所述化合物用于制备治疗缺铁性贫血的组合物的用途。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.018 秒)
